Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Arovella Reports Tumour Clearance in Gastric Cancer Animal Study, Backs Faster FDA Engagement

ALA: $0.051 +0.00% · MC: $60M

Arovella Therapeutics reported that its ALA-105 cell therapy cleared tumours in five of seven animals in a gastric cancer study, while all animals in a smaller group receiving an IL-12-armoured version survived the study with tumours eliminated; no control animals survived. The board supports advancing the program to at-scale manufacturing and seeking formal FDA engagement early next year, although the results are from an animal study.

Source announcements: 2026-10-29 08:36 to 2026-10-29 08:36 Sydney time
Story updated 2026-10-29 08:39 Sydney time
SourcesComplete tumour clearance in gastric cancer animal study
Comments